Educational Areas/Call for Grants


 

Areas of Educational Interest Available Funding Call for Grants
Cardiovascular
Acute Coronary Syndrome  
Coagulation Therapy  
High Risk Prior Myocardial Infarction  
Hypertriglyceridemia  
Heart Failure – SGLT2 Inhibition  
Secondary Prevention Acute Ischemic Stroke  
Endocrinology/Metabolic
Type 1 Diabetes  
Type 2 Diabetes  
Type 2 Diabetes – Heart Failure  
Type 2 Diabetes – Chronic Kidney Disease  
INFECTIONS & VACCINES
SARS-CoV-2 Monoclonal Antibodies  
SARS-CoV-2 Vaccine  
Nephrology
Chronic Kidney Disease - Anemia  
Chronic Kidney Disease – SGLT2 Inhibition  
Hyperkalemia  
Oncology
Advanced Breast Cancer
BRCA  
Non-BRCA  
DNA Damage Response  
PARP Inhibition  
HER2+ CGA_ONC_HER2_Breast_2101_Pathology
Metastatic HR+  
Cervical Cancer
Locally Advanced Cervical Cancer (LACC)  
Gastric Cancer
Gastric Cancer - HER2+  
Hematology
CLL (Chronic Lymphocytic Leukemia)  
MCL (Mantle Cell Lymphoma)  
HCL (Hairy Cell Leukemia)  
WM (Waldenstrom Macroglobulinemia)  
Immuno-Oncology
Bladder Cancer  
Cervical Cancer  
imAE Management  
Extensive-Stage SCLC
 
Non-Metastatic NSCLC  
iHCC (intermediate stage Hepatocellular Carcinoma)  
uHCC (unresectable Hepatocellular Carcinoma)  
Biliary Track Cancer (BTC)  
IO Diagnostics - Multidisciplinary Team  
IO Lung Diagnostics - Staging  
Neurofibromatosis
Neurofibromatosis Type 1  
Plexiform Neurofibromas  
Non-Small Cell Lung Cancer
EGFR Diagnostics & Plasma Testing  
EGFRm+ NSCLC  
HER2+ NSCLC  
Ovarian Cancer
BRCA  
Non-BRCA  
PARP Inhibition  
DNA Damage Response  
Pancreatic Cancer
BRCA  
DNA Damage Response  
PARP Inhibition  
Prostate Cancer (mCRPC)
DNA Damage Response  
Homologus Recombination Repair  
PARP Inhibition  
Respiratory
Asthma (EX-US only)  
Chronic Cough (EX-US only)  
COPD


CGA Respiratory COPD 2021 Best Practice Sharing

CGA Respiratory COPD Grand Rounds 2021 02

CGA Respiratory COPD Small Programs 2021 03

 

CRSwNP (limited budget)  
Eosinophilic Esophagitis (limited budget)  
Severe Asthma
 
Rheumatology/Immunology/Autoimmune
Systemic Lupus Erythematosus
(limited budget)
 
R & D Discovery
Scientific or educational activities designed to educate research scientists, principal researchers, drug development professionals, academics, pre-doctoral students, doctoral students and fellows. These programs must be educational and non-promotional in nature and planned, designed and implemented in accordance with the U.S. Food and Drug Administration's Guidance on Industry-Supported Scientific and Educational Activities.